Downoprazol

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Downoprazol

Quick Facts

Property Description
Active Ingredients Omeprazole, Sodium Bicarbonate
Form Oral Capsule or Powder for Suspension (Immediate-Release)
Pharmacological Class Proton Pump Inhibitor (PPI) and Antacid
Origin Synthetic
Route of Administration Oral

What Type of Medicine is Downoprazol?

Downoprazol is a synthetic combination medicine classified as a gastrointestinal agent, combining a Proton Pump Inhibitor (Omeprazole) with an Antacid (Sodium Bicarbonate). Omeprazole, the primary agent, belongs to the first generation of the PPI class, recognized for its ability to significantly reduce acid secretion. This drug is utilized for its role in rapidly alleviating symptoms associated with excess stomach acid, such as heartburn. This dual-component preparation is an immediate-release formulation intended for oral administration, setting its kinetic profile apart from conventional delayed-release PPIs. The fundamental purpose of this drug type is to provide simultaneous and sustained control over conditions related to problematic gastric acid levels.

The Key Difference: Composition and Fast-Acting Design

The composition of Downoprazol is strategically engineered to enhance therapeutic speed through the synergistic effects of its two active ingredients. Omeprazole provides the essential, long-term acid reduction via irreversible inhibition of the gastric H^+/K^+-ATPase enzyme. The co-administered Sodium Bicarbonate serves a crucial buffering role, functioning as a rapidly acting antacid to effect acid neutralization. This rapid pH elevation protects the acid-sensitive Omeprazole from degradation within the stomach, ensuring bioavailability enhancement and accelerating its entry into the bloodstream. The combination of Omeprazole with Sodium Bicarbonate supports enhanced bioavailability, contributing to faster action. This unique design enables the dual action of rapid comfort alongside the robust, sustained gastroprotection characteristic of the PPI class.

What side effects are possible with Downoprazol?

Possible Side Effects and Safety Information

The official safety profile for Downoprazol (Omeprazole/Sodium Bicarbonate) is classified by regulatory authorities based on the frequency and the physiological system affected. The most Common adverse reactions documented in regulatory sources typically involve Gastrointestinal Disorders, such as abdominal pain, flatulence, diarrhea, nausea, and vomiting. Headache is also a frequently listed event.

Frequency Classification

Category Examples (as per official regulatory data)
Common Headache, Diarrhea, Abdominal pain, Nausea, Vomiting, Flatulence
Uncommon Dizziness, Insomnia, Rash, Dermatitis
Rare Hypersensitivity reactions (e.g., Anaphylaxis), Interstitial nephritis
Not Known Hypomagnesemia, Clostridium difficile Associated Diarrhea (CDAD)

Serious Reactions and Safety Patterns

The prescribing information details several Serious Adverse Reactions. These include severe, immediate reactions like Anaphylactic shock and rare but significant conditions such as Acute Interstitial Nephritis and Severe Cutaneous Adverse Reactions (SCARs). The risk of CDAD is also officially documented.

Safety concerns specifically associated with long-term use (typically one year or more) are also noted. These duration-related patterns include an increased risk of Bone fractures, Vitamin B12 deficiency, and Hypomagnesemia.

Population-Specific and Use Constraints

Official documents state that the medicine is formally Contraindicated in patients with known hypersensitivity to any component. Caution is also noted for the Sodium Bicarbonate component in patients with renal impairment due to the potential for impaired sodium excretion. The antacid component is further contraindicated in individuals with pre-existing metabolic alkalosis or hypocalcemia.

Overdose and Emergency Response

Overdose and When to Seek Help

The following information is strictly based on official regulatory documentation concerning omeprazole/sodium bicarbonate overdose.

Documented Overdose Manifestations

Symptoms associated with Downoprazol overdosage are generally described as transient and may be variable. Officially documented presentations include confusion, headache, drowsiness, nausea, blurred vision, and tachycardia (increased heart rate). Systemic effects such as diaphoresis (increased sweating), flushing, and dry mouth have also been noted in regulatory reports. Available data indicate no serious clinical outcome has been formally reported following omeprazole overdosage.


Emergency Actions and Treatment

Category Official Regulatory Statement
Immediate Action Required Individuals must get medical help or contact a Poison Control Center right away when overdose is suspected, as mandated by official labeling.
Antidote Status No specific antidote is known for omeprazole overdosage.
Management Approach Treatment for overdosage must be symptomatic and supportive. The active component is not readily dialyzable.

Specific Overdose Consideration

Caution is noted due to the Sodium Bicarbonate component, which may impact individuals with pre-existing conditions concerning acid-base balance, such as respiratory alkalosis, as stated in the regulatory documentation.

Therapeutic Uses of Downoprazol

What Downoprazol Treats: Main Uses and Benefits

Downoprazol is a combination medication that is applied in addressing conditions marked by increased physiological stress caused by excessive stomach acid. The drug contains two ingredients relevant in contexts marked by increased discomfort or tension. The combination is relevant in contexts involving heightened systemic burden, easing the overall symptom burden associated with gastric acid.

The therapeutic utility of this medication is commonly used across conditions presenting with acute episodes. It is considered relevant for managing active duodenal and benign gastric ulcers and supports patients dealing with symptoms related to physical discomfort like heartburn associated with Gastroesophageal Reflux Disease (GERD) and erosive esophagitis (EE). The drug also may assist with supportive care in contexts involving heightened systemic burden such as upper gastrointestinal issues in critically ill patients.

The antacid component assists with an initial functional response against symptoms. This combination helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Support for symptoms related to heightened physiological activity (Heartburn and Acid Reflux)

The medication may be part of symptomatic management to help patients cope more steadily with symptom fluctuations.

“The combination contributes to offering supportive relief when symptoms interfere with routine activities related to acid-peptic disorders.”

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Downoprazol

This information reflects the official population eligibility and non-eligibility rules documented by government regulatory agencies.


Absolute Exclusions (Contraindications)

Classification Populations/Conditions
Contraindicated Patients with known hypersensitivity to omeprazole (Downoprazol), any substituted benzimidazoles, or any inactive ingredients in the specific formulation.
Contraindicated Patients receiving concomitant therapy with rilpivirine-containing products or nelfinavir, due to the risk of significant drug-level reduction that may lead to loss of therapeutic effect for the antiretroviral medication.

Restricted or Conditional Use

Age-Related Eligibility:

  • Adults (18 years) are eligible for all established uses.
  • Pediatric patients are eligible for specific indications (e.g., symptomatic GERD, Erosive Esophagitis) but only above certain age thresholds (e.g., 1 month or 1 year, depending on the indication).
  • Use is not established in infants below one month of age for any indication.

Condition-Specific Rules:

  • Hepatic Impairment: Patients with significant liver disease require caution and may necessitate a dose reduction or monitoring.
  • Gastric Malignancy: Symptom improvement with Downoprazol does not rule out the presence of stomach cancer; diagnostic follow-up is necessary for adult patients with recurring symptoms.

What should I know about interactions with other medicines?

Downoprazol’s official interaction profile is governed by two main factors: the metabolic activity of Omeprazole and the combined acid-reducing effect of the dual components, leading to pharmacokinetic and pharmacodynamic interactions.

Contraindicated and Exposure-Altering Interactions

The co-administration of Downoprazol with the antiviral Nelfinavir is formally contraindicated because the combination significantly reduces the plasma concentration of Nelfinavir.

The Omeprazole component is a documented moderate inhibitor of the CYP2C19 enzyme. This pharmacokinetic interaction may increase the systemic exposure of co-administered drugs metabolized by this pathway, including Warfarin, Phenytoin, Diazepam, and Cilostazol. Conversely, the co-administration of Omeprazole significantly reduces the active metabolite exposure of the antiplatelet agent Clopidogrel.

Gastric pH-Dependent Interactions and Timing Rules

The acid-reducing effect results in a pharmacodynamic interaction that reduces the systemic exposure and efficacy of medicines requiring an acidic stomach environment for optimal absorption. This interaction affects drugs such as the antivirals Atazanavir and antifungals like Ketoconazole and Itraconazole. Co-administration may also increase the plasma concentrations of the immunosuppressant Tacrolimus and Methotrexate. The regulatory label also specifies a timing-based administration rule: Downoprazol must be administered at least 60 minutes prior to a meal.

Mechanism of Action

The mechanism of Downoprazol is a dual-action system that couples immediate chemical neutralization with sustained, irreversible enzyme inhibition to modulate the physiological output of gastric acid.


Irreversible Blockade of Acid Secretion

This domain centers on Omeprazole and its specific molecular interaction with the H^+/ K^+- ATPase enzyme (the proton pump) on the gastric parietal cell. . Omeprazole's active form permanently binds to this pump, thereby suppressing the final common pathway for Hydrogen ion ( H^+) secretion into the stomach lumen. This mechanism results in a substantial, sustained suppression of Hydrogen ion transport.


Rapid Buffering and Mechanistic Acceleration

This domain covers the action of Sodium Bicarbonate, which immediately neutralizes the existing concentration of Hydrochloric acid ( HCl) through a rapid chemical buffering reaction. The resulting increase in pH also protects the Omeprazole molecule from degradation, enhancing its stability and ensuring faster systemic absorption. This synergistic action results in accelerated engagement of the sustained H^+/ K^+- ATPase inhibition mechanism.

Dosage and Administration Information

Administration scope

Field Detail
Route of administration Oral (via capsule, prepared suspension, or nasogastric/orogastric tube).
Dosing schedule (Adults) Standard: 20 mg once daily. Higher Dose: 40 mg once daily.
Timing in relation to meals Must be taken on an empty stomach, at least one hour before a meal.
Course Duration Typically 4 to 8 weeks for healing; up to 12 months for maintenance.
Special procedural conditions The capsule must be swallowed whole. 20 mg and 40 mg strengths are not interchangeable.

Resulting procedural structure

Official step sequence:

  • Administer the medicine on an empty stomach at least one hour before the day’s meal.
  • Take the established dose (20 mg or 40 mg) once daily according to the treatment course.
  • If a dose is missed, take it only if there are at least 12 hours before the next scheduled dose; otherwise, skip the dose.

Connection to the overall use protocol:

The administration guidelines establish a rigid protocol centered on oral administration and precise pre-meal timing to ensure the drug's intended action. This structure defines the correct quantity and regularity for each treatment course, specifying short-term limits for healing phases and distinguishing a unique, intensive schedule reserved for high-risk, inpatient contexts using the 40 mg suspension. Furthermore, dose adjustment may be considered in patients with severe hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Downoprazol

Evidence for Short-Term Treatment of Ulcers

The research for this medicine was evaluated in adults diagnosed with active ulcers in the stomach (benign gastric ulcers) or the small intestine (duodenal ulcers). The studies primarily examined outcomes such as the endoscopic healing rates—a measurement of how much the tissue lining had closed—and the patterns of patient-reported outcomes describing perceived discomfort. Studies reported measurements of mucosal healing over the short-term observation period. Some trials described initial measurements of gastric pH (a measure of acid levels), which were compared to observations from the delayed-release form of the PPI. This evidence contributed to the broader evidence landscape regarding symptom patterns over the defined observation intervals. However, the evidence base is primarily short-term, with limited information for long-term outcomes regarding recurrence rates.

Evidence for Managing GERD Symptoms and Erosive Esophagitis (EE)

For conditions related to acid reflux, such as symptomatic Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE), the research has used Randomized Controlled Trials (RCTs) and physiological studies that monitored changes in gastric acid levels. Studies focused on outcomes related to physical discomfort and success in the relief of symptoms like heartburn. Research explored the relationship between the rapid antacid component and the observed patterns in acid suppression. Clinical trials reported how symptoms evolved in the observed populations, with research exploring how the combination related to short-term changes in episodic or acute acid-related discomfort. Findings indicate that the formulation was observed in some studies to have results related to healing that were similar to standard omeprazole.

Evidence in High-Risk, Acute Care Settings

Studies were conducted in a very specific population: critically ill adult patients who face a heightened risk of upper gastrointestinal bleeding. The research utilized short-term RCTs, including trials comparing the specialized oral suspension formulation to other agents evaluated in similar contexts. Research examined outcomes related to physiological strain or stress, with the primary outcome being the incidence of clinically significant upper GI bleeding. Studies reported measurements of bleeding events over the short-term observation period. It is important to understand that the results apply only to the populations studied—specifically, critically ill adults in acute care.

Long-Term Evidence and Durability of Effect

The research includes controlled maintenance studies that tracked patients over periods extending up to twelve months for patients whose Erosive Esophagitis had healed. These studies focused on outcomes reflecting daily functioning or activity level and endoscopic measurements of the esophageal lining. Findings describe patterns in patients who continued use and were monitored for maintenance of the healed state. However, long-term effects are not fully established, as research on maintenance of healing does not generally extend beyond one year.

Evidence in Special Patient Groups and Research Gaps

Research was explored in critically ill adult patients but data for certain groups remain limited. Research regarding the use in pediatric patients is not extensively available, and the safety and effectiveness have not been established for this age group. A key research limitation is that comparative evidence is lacking for large-scale studies directly comparing the overall therapeutic outcomes of the immediate-release combination product to standard, delayed-release omeprazole for all approved indications. Research continues to explore how this formulation relates to the broader evidence landscape for acid-related disorders.

Key Studies & References

  1. Efficacy and safety of omeprazole/sodium bicarbonate immediate-release combination vs. omeprazole delayed-release for duodenal ulcer: a randomized controlled trial
  2. Long-term maintenance therapy with omeprazole/sodium bicarbonate immediate-release for healed erosive esophagitis: a 12-month study

Frequently Asked Questions (FAQ)

Common questions about Downoprazol (FAQ)


Q: Do you get withdrawal symptoms if you stop taking Downoprazol suddenly?

A: Official regulatory documents do not explicitly use the term 'withdrawal symptoms' when describing discontinuation. Official guidance exists regarding the proper method for stopping this medication, but the label does not detail a specific syndrome of symptoms that occurs immediately upon cessation.


Q: Is it true that Downoprazol can affect B12 absorption?

A: Yes, official product information states that prolonged therapy with this drug may lead to reduced absorption of Vitamin B12 (cyanocobalamin). This effect is due to the sustained reduction of stomach acid caused by the drug's primary component.


Q: Can older adults take Downoprazol without increased risk?

A: Regulatory information addresses the use of the omeprazole component in the geriatric population. The regulatory label indicates that caution is advised, and a potential dose adjustment may be necessary for patients over 60 years of age due to expected higher drug concentrations.


Q: Has Downoprazol been studied in children or adolescents?

A: Official regulatory agencies have established that the medicine may be used for specific indications, such as GERD and Erosive Esophagitis. Specific age thresholds are listed on the regulatory label for use in children for certain indications.


Q: Can I take Downoprazol with my blood pressure medicine?

A: The omeprazole component in this medicine is known to interact with certain medications that are processed by the CYP2C19 enzyme in the liver. Official documents advise monitoring when this medicine is used alongside other drugs that fall into this class, which may include some blood pressure medications.


Q: Can I take other stomach medications with Downoprazol?

A: Regulatory information indicates that this medicine’s powerful acid-reducing effect can alter the absorption of other medicines that require an acidic stomach environment to be effective. Regulatory documents warn that co-administering this drug with other stomach medications may necessitate specific timing to avoid pharmacokinetic changes.


Q: Is it possible to be allergic to Downoprazol?

A: Yes, the medicine is formally contraindicated in patients with a known hypersensitivity or allergy to any of its components. Severe allergic reactions, including anaphylaxis, are listed in official documents as a potential adverse reaction.


Q: Is Downoprazol safe for use during pregnancy or breastfeeding?

A: Official guidance indicates that use during pregnancy is advised only when the potential benefit is determined to outweigh the potential risk. Regarding breastfeeding, information indicates that the drug’s components have been observed in human milk.


Q: Does Downoprazol affect the results of lab tests?

A: Official information indicates the medicine may interfere with certain diagnostic tests, such as those used for specific neuroendocrine tumors, due to its effect on gastric acid levels.


Q: Does Downoprazol cause anxiety or changes in mood?

A: Official safety data lists central nervous system effects such as dizziness and insomnia as documented side effects. While anxiety and mood changes are not commonly listed, the official safety data covers a range of postmarketing experiences for the omeprazole component.


Q: Does Downoprazol cause dry mouth or changes in taste?

A: Although not listed as common side effects, related effects like mouth irritation or changes in taste have been noted in postmarketing reports for the omeprazole component.


Q: Are there different strengths of Downoprazol tablets?

A: Yes, regulatory documents list available dosage forms and strengths. These typically include different strengths of capsules or the powder used to prepare the oral suspension.


Q: Is it normal to have some stomach upset when beginning Downoprazol?

A: Official safety data lists several gastrointestinal side effects as common occurrences with this medicine. These include abdominal pain, diarrhea, nausea, and vomiting.


Q: Why is Downoprazol sometimes prescribed for throat issues?

A: The medicine is officially approved for conditions like symptomatic Gastroesophageal Reflux Disease (GERD) and Erosive Esophagitis (EE). These conditions involve the reflux of stomach acid, which can cause painful symptoms higher up, sometimes perceived as throat issues.


Q: Can Downoprazol affect my sleep or cause insomnia?

A: Official safety data lists insomnia (difficulty sleeping) as an uncommon adverse reaction associated with the use of this medication.


Q: What happens if I accidentally miss a dose of Downoprazol?

A: Official instructions outline a rule regarding taking a missed dose only if a specific time window remains before the next scheduled dose. Otherwise, the official instruction is to simply skip the missed dose.


Q: Why does Downoprazol sometimes cause joint or muscle pain?

A: While joint or muscle pain is not listed as a common side effect, adverse reactions such as joint pain (arthralgia) have been noted in the postmarketing surveillance for PPIs. This indicates the possibility of such pain as a rare event related to the omeprazole component.


Q: Does Downoprazol interact with supplements like magnesium or calcium?

A: Official documents warn that long-term use may lead to low magnesium levels (hypomagnesemia). Furthermore, the chronic use of the antacid component with calcium supplements can lead to a condition called milk-alkali syndrome, which is a safety concern.


Q: How quickly should I expect Downoprazol to start working?

A: Official information notes that this immediate-release formulation is designed for a rapid onset of action and faster absorption than conventional PPIs.


Q: Is Downoprazol the same as [Common similar drug name]?

A: Downoprazol is a unique combination product. It contains the acid-reducing ingredient omeprazole, a PPI, combined with the antacid sodium bicarbonate, which distinguishes it from products that contain omeprazole alone.


Q: What's the difference between Downoprazol and other PPIs?

A: The key difference is that Downoprazol is an immediate-release combination product. This unique design is intended to provide faster absorption and onset of action compared to conventional delayed-release PPIs.


Q: Does Downoprazol interact with common pain relievers like ibuprofen?

A: Regulatory information advises caution when using the drug with other medications metabolized by the CYP2C19 enzyme. It does not specifically list all common pain relievers, but it provides a general caution regarding the co-administration of drugs that use this metabolic pathway.


Q: Are there any major diet changes required when on Downoprazol?

A: Official administration instructions mandate a specific timing rule, requiring the medicine to be taken on an empty stomach at least one hour before a meal to ensure proper absorption and effectiveness.


Q: Why is Downoprazol often taken before a meal?

A: Official information explains that taking the medicine before a meal ensures that its omeprazole component is absorbed quickly. This timing allows the medication to fully suppress acid production before a meal stimulates the stomach to release large amounts of acid.

How should Downoprazol be stored and disposed of?

How to Store and Dispose of Downoprazol?

The storage and disposal instructions for this medicine are defined by regulatory labeling to ensure product stability and safety.

Required Storage Conditions

The requirements vary by formulation status:

  • Dry Form (Capsules/Powder): Store at a controlled room temperature, specifically between 20°C to 25°C. This formulation must also be protected from moisture and kept in its original, tightly closed container.
  • Reconstituted Suspension: Requires refrigerated storage between 2°C to 8°C. Do not freeze this liquid form.

Stability and Safety Rules

Constraint Requirement
In-Use Stability The refrigerated suspension must be discarded after 30 days.
Child Safety Store the product out of the sight and reach of children.

Disposal

All unused, expired product must be disposed of according to local and national regulations for pharmaceutical waste, often utilizing authorized drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Downoprazol found in:

A-Z Index: